Literature DB >> 11689384

Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects.

F Llach1, F Velasquez Forero.   

Abstract

Secondary hyperparathyroidism occurs early in the course of chronic renal failure. Early in the course, a deficit of calcitriol and an abnormality in the calcium sensor receptor may be the important factors; later, with advanced renal failure, hyperphosphatemia becomes an additional important pathogenic factor. Important clinical problems in dialysis patients are as follows: (1) hyperphosphatemia, which contributes to high morbidity and mortality of dialysis patients (a clinical approach to maintaining a normal serum phosphorus is essential and is discussed in this review); (2) a high calcium X phosphorus product leading to coronary artery calcifications (factors leading to calcifications are also discussed); and (3) calciphylaxis, which has been observed with increasing frequency in these patients (an increase in the total calcium load may be the most important pathogenic factor leading to this syndrome). Therapeutic considerations regarding the use of new vitamin D analogues devoid of a hypercalcemic and/or a hyperphosphatemic effect are also mentioned.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689384     DOI: 10.1053/ajkd.2001.28113

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

1.  [Analgesic therapy of calciphylaxis with levomethadone : a case study].

Authors:  M Poels; R Joppich; K Gerbershagen; F Wappler
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

Review 2.  Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Panpan Cai; Xiaohong Tang; Wei Qin; Ling Ji; Zi Li
Journal:  Int Urol Nephrol       Date:  2016-01-09       Impact factor: 2.370

3.  Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].

Authors:  Mark Nuijten; Daniela P Roggeri; Alessandro Roggeri; Paolo Novelli; Thomas S Marshall
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

Review 4.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

5.  The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism.

Authors:  Kerstin M Ivarsson; Shahriar Akaberi; Elin Isaksson; Eva Reihnér; Rebecca Rylance; Karl-Göran Prütz; Naomi Clyne; Martin Almquist
Journal:  Nephrol Dial Transplant       Date:  2015-09-15       Impact factor: 5.992

6.  Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.

Authors:  Mark Nuijten; Dennis L Andress; Steven E Marx; Alistair S Curry; Raimund Sterz
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Cardiovascular and Cerebrovascular Events After Parathyroidectomy in Patients on Renal Replacement Therapy.

Authors:  Kerstin M Ivarsson; Shahriar Akaberi; Elin Isaksson; Eva Reihnér; Tomasz Czuba; Karl-Göran Prütz; Naomi Clyne; Martin Almquist
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

8.  Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.

Authors:  Wacharee Seeherunvong; Obioma Nwobi; Carolyn L Abitbol; Jayanthi Chandar; José Strauss; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2006-08-10       Impact factor: 3.714

Review 9.  Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.

Authors:  Abhijit Jagdale; David K C Cooper; Hayato Iwase; Robert S Gaston
Journal:  Xenotransplantation       Date:  2018-11-20       Impact factor: 3.907

10.  Calciphylaxis in chronic renal failure: An approach to risk factors.

Authors:  W Rezaie; H A J M Overtoom; M Flens; R J L Klaassen
Journal:  Indian J Nephrol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.